These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32189003)

  • 1. Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study.
    Surial B; Ledergerber B; Calmy A; Cavassini M; Günthard HF; Kovari H; Stöckle M; Bernasconi E; Schmid P; Fux CA; Furrer H; Rauch A; Wandeler G;
    J Infect Dis; 2020 Jul; 222(4):637-645. PubMed ID: 32189003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
    Surial B; Béguelin C; Chave JP; Stöckle M; Boillat-Blanco N; Doco-Lecompte T; Bernasconi E; Fehr J; Günthard HF; Schmid P; Walti LN; Furrer H; Rauch A; Wandeler G;
    J Acquir Immune Defic Syndr; 2020 Oct; 85(2):227-232. PubMed ID: 32925387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal function change after switching tenofovir disoproxil fumarate for tenofovir alafenamide in the HIV-positive patients of a metropolitan sexual health service.
    Turner D; Drak D; O'Connor CC; Templeton DJ; Gracey DM
    AIDS Res Ther; 2019 Dec; 16(1):40. PubMed ID: 31810490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 copies/mL: does estimated glomerular filtration rate matter?
    Vergori A; Gagliardini R; Gianotti N; Gori A; Lichtner M; Saracino A; De Vito A; Cascio A; Di Biagio A; Monforte AD; Antinori A; Cozzi-Lepri A;
    Int J Antimicrob Agents; 2020 Dec; 56(6):106154. PubMed ID: 32919008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated glomerular filtration rate slopes on tenofovir alafenamide.
    Ibrahim F; Campbell L; Bailey AC; Stockwell S; Waters L; Orkin C; Johnson M; Gompels M; De Burgh-Thomas A; Jones R; Schembri G; Mallon PW; Post FA
    HIV Med; 2020 Oct; 21(9):607-612. PubMed ID: 33021067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on estimated glomerular filtration rate slope in patients with HIV: A retrospective observational study.
    Hikasa S; Shimabukuro S; Hideta K; Higasa S; Sawada A; Tokugawa T; Tanaka K; Yanai M; Kimura T
    J Infect Chemother; 2022 Mar; 28(3):396-400. PubMed ID: 34896027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort.
    Surial B; Cavassini M; Calmy A; Fehr J; Stöckle M; Bernasconi E; Roth B; Fux CA; Kovari H; Furrer H; Rauch A; Wandeler G;
    BMC Infect Dis; 2019 Oct; 19(1):834. PubMed ID: 31601174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
    Sarowar A; Coffin CS; Fung S; Wong A; Doucette K; Truong D; Conway B; Haylock-Jacobs S; Ramji A; Hansen BE; Janssen HLA; Cooper C
    J Acquir Immune Defic Syndr; 2022 Dec; 91(4):368-372. PubMed ID: 36288543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal function in Japanese HIV-1-positive patients who switch to tenofovir alafenamide fumarate after long-term tenofovir disoproxil fumarate: a single-center observational study.
    Abe K; Obara T; Kamio S; Kondo A; Imamura J; Goto T; Ito T; Sato H; Takahashi N
    AIDS Res Ther; 2021 Dec; 18(1):94. PubMed ID: 34876151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort.
    Teira R; Diaz-Cuervo H; Aragão F; Muñoz J; Galindo P; Merino M; de la Fuente B; Sepúlveda MA; Domingo P; García J; Castaño M; Ribera E; Geijo P; Romero A; Peraire J; Deig E; Roca B; Martínez E; Estrada V; Montero M; Berenguer J; Espinosa N
    HIV Res Clin Pract; 2021 Jun; 22(3):78-85. PubMed ID: 34410219
    [No Abstract]   [Full Text] [Related]  

  • 11. Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIV.
    Damas J; Munting A; Fellay J; Haerry D; Marzolini C; Tarr PE; Steffen A; Braun DL; Stoeckle M; Bernasconi E; Nawej Tshikung O; Fux CA; Darling KEA; Béguelin C; Wandeler G; Cavassini M; Surial B;
    Clin Infect Dis; 2024 Oct; 79(4):990-998. PubMed ID: 38606792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.
    Surial B; Mugglin C; Calmy A; Cavassini M; Günthard HF; Stöckle M; Bernasconi E; Schmid P; Tarr PE; Furrer H; Ledergerber B; Wandeler G; Rauch A;
    Ann Intern Med; 2021 Jun; 174(6):758-767. PubMed ID: 33721521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate.
    Campbell L; Barbini B; Burling K; Cromarty B; Hamzah L; Johnson M; Jones R; Samarawickrama A; Williams D; Winston A; Post FA;
    J Acquir Immune Defic Syndr; 2021 Oct; 88(2):214-219. PubMed ID: 34506361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back.
    Milinkovic A; Berger F; Arenas-Pinto A; Mauss S
    AIDS; 2019 Dec; 33(15):2387-2391. PubMed ID: 31764103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B.
    Nam H; Han JW; Lee SK; Yang H; Lee HL; Sung PS; Song MJ; Kwon JH; Jang JW; Chang UI; Kim CW; Nam SW; Bae SH; Choi JY; Yoon SK; Yang JM; Kim HY
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1673-1683. PubMed ID: 38690711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
    DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
    Mills A; Crofoot G; McDonald C; Shalit P; Flamm JA; Gathe J; Scribner A; Shamblaw D; Saag M; Cao H; Martin H; Das M; Thomas A; Liu HC; Yan M; Callebaut C; Custodio J; Cheng A; McCallister S
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):439-45. PubMed ID: 25867913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.
    Kovari H; Surial B; Tarr PE; Cavassini M; Calmy A; Schmid P; Bernasconi E; Rauch A; Wandeler G; Ledergerber B;
    HIV Med; 2021 Aug; 22(7):623-628. PubMed ID: 33880839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting.
    Kauppinen KJ; Kivelä P; Sutinen J
    AIDS Patient Care STDS; 2019 Dec; 33(12):500-506. PubMed ID: 31742421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial.
    Hamzah L; Williams D; Bailey AC; Jones R; Ibrahim F; Musso CG; Burling K; Barbini B; Campbell L; Post FA;
    HIV Med; 2020 Mar; 21(3):198-203. PubMed ID: 31679186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.